Muromonab-CD3 (brand name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant medication given to reduce acute rejection in people with organ transplants. [1] [2] It is a monoclonal antibody targeted at the CD3 receptor, [3] a membrane protein on the surface of T cells.

OKT3 has been found to be effective for induction of immunosuppression and for treating initial and steroid-resistant rejections. OKT3 is a murine monoclonal antibody of the immunoglobulin IgG2a isotype.

2024年3月25日 · Orthoclone OKT3 package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

Muromonab-CD3 (also known as OKT3) is a murine IgG2a antibody directed at the ɛ-chain of CD3 that was first used in the setting of renal transplant induction therapy in the 1980s: it was shown to be effective in the treatment of acute allograft rejection.

Muromonab CD3 (Orthoclone OKT3, Orthoclone, OKT3) is the first monoclonal antibody to become available for therapy in humans. In effect it blocks all cytotoxic T cell function. Clinical trials show that muromonab CD3 is effective in reversing acute renal, hepatic, cardiac and combined kidney-pancrea …

The OKT3 monoclonal antibody has unique reactivity for human T cells and induces a mitogenic response equal to that of concanavalin A (Con A). However, significant differences were found in activation requirements for the two T cell mitogens.

2020年12月28日 · Muromonab-CD3 is a mouse monoclonal antibody to CD3, often referred to as OKT3, which was withdrawn from use in 2010 but was previously used to treat acute cellular rejection after solid organ transplantation.

1993年8月1日 · OKT3 is a monoclonal antilymphocyte antibody produced by a murine hybridoma technique. It differs from polyclonal antilymphocyte antibody preparations in that it is specific for one epitope of the T lymphocyte and is a pure product with batch-to-batch standardization.

Parenteral OKT3 is used to treat transplant rejection and a humanized anti-CD3 Mab has shown positive clinical effects in new onset diabetes. Oral administration of anti-CD3 has not been tested in humans, but suppresses autoimmunity in animal models.

The murine monoclonal anti-T-cell antibody, OKT3, has been used during the past 9 years in various clinical transplantation studies. Its use in clinical organ transplantation has advanced the science of MoAb use in humans and has provided a vast amount of evidence substantiating the importance of MoAbs in clinical medicine.